Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $73.43

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned an average recommendation of “Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. Nine research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $73.43.

Several research firms have commented on JSPR. Evercore ISI restated an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Monday, August 26th. Stifel Nicolaus started coverage on shares of Jasper Therapeutics in a research report on Thursday, June 27th. They set a “buy” rating and a $86.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a report on Tuesday, June 18th. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, August 13th. Finally, Royal Bank of Canada reduced their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th.

Jasper Therapeutics Stock Performance

JSPR stock opened at $19.41 on Thursday. The company has a 50 day moving average price of $19.73 and a two-hundred day moving average price of $22.65. The stock has a market capitalization of $292.39 million, a P/E ratio of -3.45 and a beta of 2.21. Jasper Therapeutics has a one year low of $4.00 and a one year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. Research analysts forecast that Jasper Therapeutics will post -4.16 earnings per share for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. boosted its position in shares of Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares during the period. Virtu Financial LLC acquired a new stake in Jasper Therapeutics in the first quarter valued at approximately $306,000. Rhumbline Advisers purchased a new stake in shares of Jasper Therapeutics during the second quarter valued at approximately $300,000. Concurrent Investment Advisors LLC acquired a new position in shares of Jasper Therapeutics during the first quarter worth $599,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Jasper Therapeutics during the second quarter worth $740,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.